Final two-year data from the Phase 3 VISIONARY trial indicate that Voyxact (sibeprenlimab-szsi) may significantly slow progression of primary immunoglobulin A nephropathy (IgAN), preserving kidney function and reducing the likelihood of kidney failure events in patients at high risk of disease progression.
A recent report by Otsuka, the findings of which were presented at ASN Kidney Week 2026 and simultaneously published in The New England Journal of Medicine, represents one of the most comprehensive datasets reported in IgAN to date. Investigators reported that treatment with the selective APRIL inhibitor resulted in sustained kidney function stabilization over two years, alongside substantial reductions in proteinuria and other markers of disease activity.
Marked Reduction in Kidney Disease Progression
The global, randomized, placebo-controlled VISIONARY study enrolled 510 adults with primary IgAN who were considered at risk for progressive kidney disease. Over the two-year study period, a composite kidney outcome occurred in just one patient receiving Voyxact, compared with 28 patients in the placebo arm. This translated into a 97.1% reduction in the risk of kidney function decline or kidney failure.
Results across individual components of the composite endpoint also favored sibeprenlimab. Patients treated with the drug experienced fewer cases of sustained decline in estimated glomerular filtration rate (eGFR), fewer instances of serum creatinine doubling, and fewer episodes of severe kidney impairment. Notably, no patients receiving Voyxact required kidney replacement therapy during the study, whereas five placebo-treated patients did.
Kidney Function Remained Stable Over Two Years
Investigators reported a positive annualized eGFR slope of +0.3 mL/min/1.73 m²/year with Voyxact, compared with a decline of -4.2 mL/min/1.73 m²/year in the placebo group. The treatment effect of +4.5 mL/min/1.73 m²/year was statistically significant and consistent across key patient subgroups.
By month 24, patients receiving Voyxact demonstrated a slight improvement from baseline kidney function, while those receiving placebo experienced a substantial decline. The between-group difference of 9.2 mL/min/1.73 m² highlighted the therapy’s potential to preserve renal function over time.
Researchers noted that these outcomes align with updated KDIGO treatment goals aimed at slowing kidney function loss to near-physiologic rates, a benchmark associated with minimizing long-term disease progression.
Sustained Impact on Proteinuria and Hematuria
The therapy also produced durable reductions in proteinuria, a major indicator of kidney damage in IgAN. At two years, treatment was associated with a 61.3% reduction in 24-hour urine protein-to-creatinine ratio compared with baseline.
In addition, hematuria resolution was observed in a substantially larger proportion of patients receiving Voyxact. Nearly 79% of participants with baseline hematuria achieved a negative dipstick result, compared with approximately 20% of those receiving placebo.
Favorable Safety Profile Maintained
Safety findings remained consistent throughout the two-year study period. Rates of overall adverse events, infections, and injection-site reactions were similar between treatment groups. No new safety concerns emerged during follow-up.
Serious infections occurred less frequently among patients receiving Voyxact than among those receiving placebo. Investigators also reported lower rates of severe adverse events and treatment discontinuations in the active-treatment arm.
Targeting APRIL in IgAN
Voyxact is a humanized monoclonal antibody designed to selectively inhibit APRIL (A Proliferation-Inducing Ligand), a key contributor to IgAN pathogenesis. APRIL promotes production of galactose-deficient IgA1, a pathogenic molecule implicated in the formation of kidney-damaging immune complexes.
By targeting this pathway, the therapy aims to address an underlying driver of disease rather than solely managing symptoms or complications.
Regulatory Status and Ongoing Development
Voyxact received accelerated approval from the US Food and Drug Administration in November 2025 for reducing proteinuria in adults with primary IgAN at risk for disease progression. Otsuka has submitted data, including the two-year kidney function findings from VISIONARY, to support traditional approval.
The company is also evaluating sibeprenlimab in additional studies, including a Phase 3 pediatric IgAN trial and a Phase 2 program investigating its potential role in other immune-mediated kidney diseases such as primary membranous nephropathy, focal segmental glomerulosclerosis, and minimal change disease.
Clinical Significance
The final VISIONARY results strengthen evidence that selective APRIL inhibition may offer a disease-modifying strategy in IgAN. Beyond reducing proteinuria, the study suggests that long-term treatment with Voyxact can preserve kidney function and substantially lower the risk of progression to kidney failure, outcomes that remain central goals in the management of this chronic kidney disease.
